Dr. Bruce P. Burnett joined InflaRx in 2020 as Head of US Regulatory and Medical Affairs. He received his BS degrees in biology and chemistry from Eastern Washington University and his Master’s in Philosophy in biochemistry and PhD in molecular biophysics and biochemistry from Yale University. He is the recipient of several NIH as well as SBIR grants and has served on the ad hoc study section for review of NIH SBIR awards. Dr. Burnett has been in the pharmaceutical industry for over 25 years spending his first 8 years in drug discovery and then the last 17 in medical affairs, regulatory and compliance. His disease state experience includes women’s health (contraception, HRT-menopausal symptom relief, aesthetics-venous disease, osteopenia/osteoporosis), gastroenterology (irritable bowel syndrome, HIV-enteropathy, Crohn’s disease, ulcerative colitis, chronic diarrhea, GERD), rheumatology (osteoarthritis, rheumatoid arthritis), vascular disease (ANCA-AAV, chronic venous insufficiency, deep vein thrombosis and hemorrhoids), dermatology (hidradenitis suppurativa, pyoderma grangenosum, cutaneous squamous cell carcinoma, superficial bacterial and fungal infections, pruritus, acne, plaque psoriasis), infectious disease (HIV, GI infections-H. pylori and C. difficile, endemic/systemic fungal infections) and pulmonology (COVID-19, antifungal prophylaxis in lung and bone marrow transplant patients). Dr. Burnett supports the development of new chemical entities as well as collaboration with the clinical department to advance InflaRx’s clinical programs through interactions with thought leaders in each field.